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Abstract
Background: Studies in patients with low HDL have suggested that impaired cellular cholesterol
efflux is a heritable phenotype increasing atherosclerosis risk. Less is known about the association
of macrophage cholesterol efflux with lipid profiles and CAD risk in normolipidemic subjects. We
have therefore measured macrophage cholesterol efflux in142 normolipidemic subjects undergoing
coronary angiography.
Methods:  Monocytes isolated from blood samples of patients scheduled for cardiac
catheterization were differentiated into macrophages over seven days. Isotopic cholesterol efflux
to exogenously added apolipoprotein A-I and HDL2 was measured. Quantitative cholesterol efflux
from macrophages was correlated with lipoprotein subclass distribution in plasma from the same
individuals measured by NMR-spectroscopy of lipids and with the extent of coronary artery disease
seen on coronary angiography.
Results: Macrophage cholesterol efflux was positively correlated with particle concentration of
smaller HDL and LDL particles but not with total plasma concentrations of HDL or LDL-
cholesterol. We observed an inverse relationship between macrophage cholesterol efflux and the
concntration of larger and triglyceride rich particles (VLDL, chylomicrons). Subjects with significant
stenosis on coronary angiography had lower cholesterol efflux from macrophages compared to
individuals without significant stenosis (adjusted p = 0.02).
Conclusion: Macrophage cholesterol efflux is inversely correlated with lipoprotein particle size
and risk of CAD.
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Introduction
The excessive uptake of lipoproteins by cells in the arterial
wall gives rise to cholesterol-loaded cells with foamy cyto-
plasm due to the presence of cholesteryl ester droplets
known as foam cells. These foam cells form the hallmark
of atherosclerotic plaques. The efflux of cholesterol from
foam cells is mediated by high-density lipoprotein (HDL)
or its apolipoproteins and is widely believed to represent
a crucial step in the prevention or reversal of atherosclero-
sis [1]. Macrophage cholesterol efflux has been proposed
as the initial step in the reverse cholesterol transport
(RCT), a prominent hypothesis to explain the anti-athero-
genic mechanisms of HDL [2]. Although for many years
the efllux of cholesterol was thought to occur primarily by
passive aqueous diffusion, recently it has become clear
that cholesterol efflux from macrophages is a highly regu-
lated process that is mediated by specific molecules,
including ATP-binding cassette transporters (ABC-trans-
porters). Mutations in ABCA1 have been shown to cause
Tangier-disease [3-6], a rare autosomal recessive disease
which is characterized by extremely low plasma HDL-con-
centrations, the accumulation of foam cells in various tis-
sues and moderately increased atherosclerosis
suceptibilty. Importantly, patients with this condition
show almost complete absence of cholesterol and phos-
pholipid-efflux from macrophages [7].
In the mouse model, macrophage specific knockout of
ABCA1 does not have a significant effect on HDL plasma
levels but results in increased atherosclerosis [6,8,9].
While cholesterol efflux from macrophages might play a
crucial role in foam cell development it has been demon-
strated in the mouse model that ABCA1-mediated choles-
terol efflux in the liver is primarily responsible in
determining total plasma HDL[10,11].
In humans, a number of studies have examined choles-
terol efflux from cultivated skin fibroblasts or monocyte
derived macrophages isolated from the blood of patients
with familial low HDL [12-16]. These studies suggest that
defective cholesterol efflux from macrophages is a herita-
ble cellular phenotype that cosegregates with low HDL.
In contrast to these findings, a recent study by Nakanishi
and coworkers demonstrates that serum from patients
with low HDL displays reduced cholesterol efflux capacity
whereas no difference in cellular efflux capacity was
found[17].
While the aforementioned studies have been conducted
in subjects with the rare condition of familial low HDL,
the correlation of macrophage cholesterol efflux with
plasma lipids and coronary atherosclerosis in a normolip-
idemic population has not been examined so far. To
address this problem, we have measured cholesterol efflux
from monocyte-derived macrophages in 142 patients
undergoing coronary angiography at our center and exam-
ined the relationship with plasma lipids, lipoprotein sub-
classes and coronary atherosclerosis.
Methods
Patient selection
We have randomly selected 142 patients undergoing
scheduled diagnostic coronary angiography at our center
between January 2005 and June 2007. Patients receiving
lipid lowering medication were excluded from the study.
All patients were fasting and blood was drawn by direct
venipuncture at least one hour before cardiac catheteriza-
tion was performed. Patients with acute coronary syn-
dromes, inflammatory conditions or known neoplasms
were excluded from the study. Plasma lipids were deter-
mined in the central laboratory of the Univerity of Lübeck
Hospital. This study was conducted as part of the Lübeck
Registry of Structural Heart Disease. All subjects gave
informed consent and the study protocol was approved by
the local ethics committee.
Cholesterol efflux from monocyte derived macrophages
Peripheral blood mononuclear cells (PBMCs) were sepa-
rated from whole blood by FICOLL-gradient, washed and
resuspended in cell-culture medium. Cell culture medium
used was DMEM supplemented with human serum from
a single male donor, blood group ABRh- with the same
charge being used throughout the study. 500.000 cells/
well were plated out on a 12-well plate. After 1 hour all
non-attached cells were removed by washing. Adherent
cells were cultivated for 7 days with change of medium 24
hours and 4 days after isolation of monocytes. Differenti-
ation of monocytes into macrophages was controlled in a
subset of cases by scraping cells off the plate and perform-
ing flow-cytometric analysis of macrophage differentia-
tion markers using the following monoclonals: CD16-
FITC (Beckman-Coulter); CD64-FITC (Pharmingen),
CD33-PE (Beckman); CD45PerCP (BD) and CD14-APC
(BD).
On day seven, monocyte derived macrophages were incu-
bated with 3H-labelled fetal-bovine-serum (FBS) Choles-
terol (2 μCi/ml; Amersham) plus the LXR-agonist
T0901317 (10 micromol/l, Sigma) for 24 hours followed
by extensive washes. Cells were treated with the LXR-ago-
nist T0901317 in order upregulate the capacity for choles-
terol efflux and thus achieve a more stable experimental
system[18].
Cells were then equilibrated with serum-free medium
containing 0,2% Bovine Serum Albumin (BSA) for 30
min before either apo A-I (10 microg/ml), HDL2 (20
microg/ml) or a BSA-control (0,2%) were added into sep-
arate well. For each acceptor measurements were per-Lipids in Health and Disease 2009, 8:14 http://www.lipidworld.com/content/8/1/14
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formed in triplicate. Lipid-free, recombinant apoA-I and
HDL2 from the same donor were purchased from Biode-
sign (Saco, Maine), the same charge was used throughout
the study. Cholesterol efflux from cells was stopped after
24 hours by collecting the medium and lysing the cells in
0,1 N sodium hydroxide containing 1% SDS. Cholesterol
efflux was determined as % of total cellular radioactivity
released into the medium. BSA mediated efflux was sub-
tracted from HDL2 and apoA-I mediated efflux to calcu-
late the efflux specific for each of these acceptors.
Duplicate measurement of cholesterol efflux from the
same individuals was carried out in 10% of cases. In these
subjects, a second blood sample was obtained one day
after cardiac catheterization and a separate cultivation of
cells and cholesterol efflux assay was carried out.
Plasma lipids
Blood samples from all patients were obtained during
angiography. Plasma lipids (Total-, LDL-, HDL-choles-
terol and triglycerides) were determined using standard
fluorimetric methods at the central laboratory of the Uni-
versity of Lübeck hospital. Lipoprotein subclass distribu-
tion was assessed by NMR spectroscopy and carried out at
LipoFit GmbH, Regensburg, Germany (patents: WO
2005/119285 A1, and DE 10 2004 026903 A1). Gradient-
weighted NMR spectra of blood plasma were recorded on
a Bruker 600 MHz spectrometer Avance II and revealed
characteristic overall profiles of the lipoprotein signals.
The spectral regions of the spectra ranging from 1.5 to 0.7
ppm were modelled into a set of 15 lipoprotein subclasses
and classified according to additional file 1.
Coronary angiography
All patients underwent coronary angiography and coro-
nary angiograms were read by two experienced interven-
tional cardiologists who were blinded for all other patient
information. Coronary artery disease (CAD) with signifi-
cant stenosis was defined as luminal narrowing of a major
coronary artery greater than 50%. No CAD or non-
obstructive CAD was defined by absence of lesions or by
lesions without significant luminal narrowing of the cor-
onary arteries (<50%)
Results
Characteristics of the patient population
142 patients (35 women, 107 men) undergoing coronary
angiography at our center were included in this study. 90
individuals were affected from obstructive CAD with sig-
nificant lesions resulting in luminal narrowing greater
than 50% in one or more segments. The remaining 52
individuals showed either non-significant lesions or angi-
ographic exclusion of CAD.
Baseline characteristics of the patient population are dis-
played in Additional file 1. Average plasma HDL-choles-
terol, LDL-cholesterol and total cholesterol in the overall
group were within normal limits. There was no statisti-
cally significant difference in plasma lipid or lipoprotein
particle concentration between individuals affected by
obstructive CAD and non-affected individuals with only
age and gender showing significant differences in distribu-
tion between the groups.
Correlation of macrophage cholesterol efflux with plasma 
HDL and lipoprotein subclass particle distribution
Overall, the quantitative macrophage cholesterol efflux to
exogenously added apoA-I and HDL in the total popula-
tion showed normal distribution and individual measure-
ments were highly reproducible in separate experiments
(data not shown).
Cholesterol efflux from cultivated monocyte derived-mac-
rophages cultured ex-vivo for 7 days was subsequently
compared to plasma lipid concentration and lipoprotein
subclass distribution in blood samples obtained from the
respective individual during angiography.
No significant correlation between macrophage choles-
terol efflux and total plasma HDL-levels was observed for
both apoA-I (Pearson correlation coefficient r = 0.08; p =
0.37) and HDL2 (r = -0.01; p = 0.87) dependent efflux
(figure 1). Furthermore, there was no significant correla-
tion of macrophage cholesterol efflux to total-cholesterol,
LDL-cholesterol and triglycerides (data not shown).
However, when macrophage cholesterol efflux was corre-
lated with particle concentration in the whole range of
lipoprotein subclasses, we observed a significant correla-
tion between quantitative cholesterol efflux to apoA-I and
HDL2 with particle concentration in several lipoprotein
subclasses (Figure 2, left panels). In general, this correla-
tion of macrophage cholesterol efflux to both apoA-I and
HDL2 showed an inverse correlation to the size of lipo-
protein particles (Figure 2, left panels). The correlation
was positive for the smaller and more cholesterol rich
lipoprotein subclasses (HDL [A] through HDL [D] and
LDL [A] through LDL [E]. In contrast, the correlation
proved negative for the comparably larger and triglyceride
rich lipoprotein subclasses (Chylomicrons, VLDL and
IDL).
The strongest positive correlation between macrophage
cholesterol efflux to both apoA-I and HDL2 as acceptors
concentration was observed for the smallest group of
HDL-particles (HDL [A]: r = 0.50; p = 0.0001 for efflux to
apoA-I; r = 0.37; p = 0.0001 for efflux to HDL2). The cor-
relation between individual values for cholesterol efflux
to apoA-I and HDL2 with particle concentration of HDL
[A] in plasma from the same individuals is dispayed in fig-
ure 2 (right panels).Lipids in Health and Disease 2009, 8:14 http://www.lipidworld.com/content/8/1/14
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Association of macrophage cholesterol efflux with 
obstructive CAD
Since impaired cholesterol efflux from macrophages has
been suggested to contribute to atherosclerosis develop-
ment, we next examined whether a quantitative difference
in macrophage cholesterol efflux between subjects
affected from obstructive CAD and those subjects with no
CAD or only mild disease was detectable. For cholesterol
efflux to HDL2 the average percentage of cholesterol
released into the medium in patients with obstructive
CAD (n = 90) was 46.1% (95% CI: 5,0%, StdDev: 18.5%)
compared to 50.9% (95%CI: 2.8, StdDev: 13.7%) in
patients without CAD or with non-obstructive lesions (n
= 52).
For cholesterol efflux to apoA-I as acceptor the average
percentage of cellular cholesterol released was 29.8% in
patients with obstructive CAD (95%CI: 4.2, StdDev: 15.6)
compared to 31.3% (95%CI: 3.0, StdDev: 14.35) in the
no CAD/non obstructive group (Figure 3).
Since male sex and age were risk factors significantly asso-
ciated with risk of obstructive CAD in the baseline charac-
teristics of our study population these risk factors were
included into a regression analysis. After adjusting for sex
and age we found a significant inverse correlation
between HDL2-mediated macrophage cholesterol efflux
and obstructive CAD on coronary angiogram (p = 0.02,
Figure 3). While a similar inverse correlation was observed
for efflux to apoA-I as well, it did not reach statistical sig-
nificance.
Discussion
Previous studies suggest that cholesterol efflux from
human cells grown in primary culture presents a heritable
cellular phenotype with functional correlation to lipid
metabolism and potentially the risk of coronary athero-
sclerosis. These studies were mainly undertaken in small
numbers of individuals suffering from familial HDL defi-
ciency syndromes. In contrast, our study was conducted in
a group of normolipidemic individuals undergoing
scheduled coronary angiography. In this group we have
studied the correlation of macrophage cholesterol efflux
Correlation of macrophage cholesterol efflux from patient derived macrophages onto exogenously added apoA-I (10 micro- gramm/ml; left chart) and HDL2 (20 microgramm/ml; right chart) with plasma HDL levels from a blood sample of respective  individuals obtained at the time of coronary angiography Figure 1
Correlation of macrophage cholesterol efflux from patient derived macrophages onto exogenously added 
apoA-I (10 microgramm/ml; left chart) and HDL2 (20 microgramm/ml; right chart) with plasma HDL levels 
from a blood sample of respective individuals obtained at the time of coronary angiography. Cholesterol efflux is 
expressed as % of total cellular radioactivity released into the medium after 24 hours incubation.
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with plasma lipids, lipoprotein subclass distribution and
angiographic extent of CAD. Our study hypothesis is
based on the results of previous studies suggesting that
genetically determined differences in cholesterol efflux
and other cellular functions are preserved in cells culti-
vated ex-vivo. Accordingly, if cells isolated from subjects
will have a stable functional phenoype over 7 days, it
should be informative to compare lipid profiles and ang-
iography results from these individuals obtained at base-
line with cholesterol-efflux results measured after 7 days
of culture.
In contrast to a previous study conducted in patients with
familial low HDL [15,16], we did not observe a significant
correlation between cholesterol efflux from macrophages
and plasma HDL concentration. A possible explanation
for this finding could be that macrophage cholesterol
efflux is quantitatively less important to maintain plasma
HDL levels in a normolipidemic population compared to
patients with extremely low HDL. Since animal studies
have also demonstrated that macrophage cholesterol
efflux does not have a substantial impact on plasma
HDL[6,8,9], our study supports the hypothesis that cho-
lesterol efflux from other tissues such as for example liver
or muscle is more important to determine quantitative
HDL levels.
Correlation of cholesterol efflux to HDL2 (top left) and apoA-I (bottom left) with concentration of lipoprotein particles in var- ious subclasses as determined by NMR-spectroscopy of lipids Figure 2
Correlation of cholesterol efflux to HDL2 (top left) and apoA-I (bottom left) with concentration of lipoprotein 
particles in various subclasses as determined by NMR-spectroscopy of lipids. For size definition of individual lipopro-
tein particles see Table 1. Correlation is expressed as Spearman's correlation coefficient (r) = y-axis with the level of signifi-
cance indicated for each p < 0.01. Correlation of macrophage cholesterol efflux from patient derived macrophages onto 
exogenously added HDL2 (20 microgramm/ml; top right) and apoA-I (10 microgramm/ml; bottom right) with concentration of 
HDL [A] particles in nmol/l (HDL [A] = smallest subclass of HDL particles as defined by NMR with a size of 7 to 8.5 nm). Cho-
lesterol efflux is expressed as % of total cellular radioactivity released into the medium after 24 hours incubation.Lipids in Health and Disease 2009, 8:14 http://www.lipidworld.com/content/8/1/14
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Because more subtle effects of macrophage cholesterol
efflux on the reverse cholesterol transport might not be
detectable by measuring total HDL levels, we used NMR
spectroscopy of plasma lipids to determine the lipopro-
tein subclass distribution in plasma samples of all subjects
in which macrophage cholesterol efflux had been meas-
ured. In large scale clinical studies involving human sub-
jects NMR spectroscopy of lipids has been demonstrated
as a reliable method to characterize lipoprotein subclass
distribution in plasma[15]. Interestingly, we observed an
inverse correlation between macrophage cholesterol
efflux and lipoprotein particle size on NMR spectroscopy.
While the concentration of large triglyceride-rich lipopro-
tein particles such as chylomicron-remnants or VLDL was
negatively correlated with macrophage cholesterol efflux
we found a strong positive correlation efflux with smaller,
more cholesterol rich particles in the HDL and LDL frac-
tion. This finding seems functionally plausible, since
HDL-particles in particular and to a lesser extent also LDL-
particles have been shown to promote cellular cholesterol
efflux in cell-based assays and in vivo. The positive corre-
lation was particularly strong for the smallest subclass of
HDL particles measured by NMR, which might resemble
the lipid-poor pre-β HDL particles. These pre-β HDL par-
ticles are widely believed to act as the preferential sub-
strate for ABCA1-mediated cholesterol efflux, which has
been proposed as the initiating step for the reverse choles-
terol transport. The inverse relationship of macrophage
cholesterol efflux with large triglyceride-rich lipoproteins
(TRLs) does also fit with physiological models in which
plasma HDL, HDL-turnover and lipolytic-activity are neg-
atively correlated with TRL-concentration[19].
Measuring the concentration of particles in lipoprotein
subclasses might therefore better represent the dynamic
flux in the reverse cholesterol pathway than the more
static determination of total HDL, LDL or triglyceride lev-
els.
Macrophage cholesterol efflux is believed to be anti-ather-
ogenic by preventing or reversing the development of
foam cells in the arterial wall. Since the correlation
between angiographic CAD and macrophage cholesterol
efflux has not been examined so far, we next investigated
whether a quantitative difference in cholesterol efflux
could be detected between the group of patients with
Comparison of macrophage cholesterol efflux from patient derived macrophages onto exogenously added HDL2 (20 μmol; left  chart) and apoA-I (10 μmol; right chart) according to CAD status Figure 3
Comparison of macrophage cholesterol efflux from patient derived macrophages onto exogenously added 
HDL2 (20 microgramm/ml; left chart) and apoA-I (10 microgramm/ml; right chart) according to CAD status. 
Obstructive CAD was defined as presence of lesions resulting in luminal narrowing >50% in one or more coronary artery. Dis-
played are average cholesterol efflux, 95% confidence interval (boxes) and standard deviation (error bar). *0 = 0.025 for cho-
lesterol efflux to HDL2 in patients with obstructive CAD versus controls in a univariate regression analysis adjusting for age 
and sex.
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obstructive CAD and the group without CAD or non-
obstructive lesions.
Indeed, after adjusting for sex and age we found a signifi-
cant inverse correlation between HDL2-mediated macro-
phage cholesterol efflux and obstructive CAD. For apoA-I
mediated efflux a similar trend was observable that did
not reach statistical significance.
Macrophages were preconditioned equally during the
preparation, so that it seems unlikely for these cells to be
influenced by environmental conditions or by the patho-
logical stage they were exposed to in CHD. The data there-
fore reflect more fundamental background of these cells
such as genetic factor that might cause the pathological
status. Generally speaking, the apoA-I-dependent release
should closely be associated with function of ABCA1, and
the HDL2-dependent release should be associated with
ABCG1-function or other factors that regulate the
exchange-based non-specific release. In such a view, posi-
tive correlation of the apoA-I-mediated release to HDL3
concentration may indicate that HDL3 levels reflect basic
capability of cells to generate HDL, such as activity of
ABCA1. The similar correlation of the HDL2-mediated
release may imply that expression of ABCG1 could be par-
allel to ABCA1 expression. From the pathophyiological
point of view, the ABCG1-dependent cholesterol release
might be more important than the ABCA1-dependent
release.
Our study has several limitations that need to be taken
into account when interpreting these results. Methods to
cultivate monocyte-derived macrophages and determine
cellular cholesterol efflux are at present extremely labour-
and cost-intensive and thus preclude larger case numbers.
We have included 142 subjects and our study is therefore,
to our knowledge, the largest cohort in which cellular cho-
lesterol efflux from patient derived cells was assessed.
While it is noteworthy that a difference in means between
cases and controls was detectable in our study, it will be
essential to replicate these findings in larger cohorts in the
future in order to further substantiate the role of macro-
phage cholesterol efflux as a CAD risk factor.
Conclusion
The finding that macrophage cholesterol efflux from
patient-derived cells measured ex-vivo in a serum-free sys-
tem correlates to lipoprotein particle distribution in
plasma and potentially to CAD risk indicates that this cel-
lular mechanism is to a large degree genetically deter-
mined. Identification of novel genes regulating
macrophage cholesterol efflux will be an important aim of
future research in which functional studies using patient
derived cells can be a valuable tool.
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